AVGO

Estimates disagree — look closer.

53.1% implied revenue CAGR

Today's P/S implies ~53.1% revenue CAGR for five years versus 22.0% realized growth.

0%–0%

WATCH: elite fundamentals but the current price sits at or above a conservative fair value with no variant view; monitor for a pullback toward the mid-$300s or evidence at the Q3 print that growth duration exceeds what the multiple embeds.

Strongest bear case

AVGO trades at ~71x trailing P/E, ~60x TTM EV/EBITDA, and 26x TTM sales — multiples that require the AI capex boom to persist for years without a digestion phase. The packet itself shows how fragile that is: the stock fell from $495 (2026-06-03) to well off that high and has bounced +9.1% in five days on no new fundamental data. Revenue is hyperscaler-concentrated custom-ASIC demand from a handful of customers who can in-source or dual-source to MRVL; one program reschedule flows straight through a ~$2.04T market cap priced for perfection. Meanwhile insiders (Brazeal -50k sh, Samueli, Delly, Page) sold into June-July with zero buys, and receivables turnover has deteriorated from 10.87 (2024-11) to 6.91 TTM — receivables growing much faster than sales, consistent with lumpy concentrated billings a bear would probe.

Missed / under-weighted red flags

• Receivables turnover collapsed from 10.87 (2024-11-03) to 6.91 TTM (2026-05-03) — working-capital absorption consistent with concentrated, back-loaded hyperscaler billings; not itemized in the report's risks.
• Quarterly EPS was negative (-$0.4021) as recently as 2024-08-04 and TTM P/E has exceeded 100x within six quarters — earnings power at this scale is young and untested through a downcycle.
• Beta 1.48 and a 52-week range of $281.87-$495 (a ~43% intra-year drawdown band) understate how violently the multiple reprices; position-sizing text treats WATCH as safe but a mid-$300s 'buy zone' sits inside normal volatility, not at a margin of safety.
• The +9.1% 5-day move that erased the valuation improvement occurred with no new filings in the packet (last 8-K 2026-07-06) — the rally is unexplained by packet evidence.
• Both TTM EBITDA and forward EPS in the report are derived/annualized figures with all four FMP statement endpoints failing 403 — every load-bearing quantitative claim lacks primary-statement verification.
• China/export-control risk is tagged 'medium' with no revenue-by-geography data in the packet at all — the severity rating is asserted, not evidenced.

Fair-value critique

The $420 fair value applies 22x to a consensus forward EPS (~$19.1) that is itself backed out of the packet's forwardPE — a circular anchor: it reprices consensus at consensus, so 'fair value ≈ price' is nearly tautological. Worse, $19.1 forward vs $6.01 TTM EPS implies >200% one-year EPS growth, which contradicts the packet's own decelerating growth series and suggests the forwardPE datum is unreliable. The $340 low case (18x) and $500 high (26x) inherit the same suspect denominator, so the entire range — including the mid-$300s 'pullback buy' guidance — rests on an unverified earnings number.